The Supreme Court on Monday ordered an appeals court to reconsider its decision to uphold patents held by Myriad Genetics on two genes associated with a high risk of breast and ovarian cancer. Fred R. Conrad/The New York Times
The appeals court was told to take another look at the case in light of the Supreme Court’s ruling last week that a certain diagnostic test was not eligible for patents because it was a simple application of a law of nature.
